# Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Study · id `cardio:ct-nct06858878` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06858878](<https://clinicaltrials.gov/study/NCT06858878>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06858878

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1105 participants.

## Technical summary

Registry record NCT06858878. Randomized; double masking; primary purpose treatment. Start 2025-03-17 (actual); primary completion 2027-01-21 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1105 participants (enrolled count; ClinicalTrials.gov record NCT06858878, source copy `cardio:ctgov-nct06858878-2025-12-31`, retrieved 2026-10-26)
- Started: 2025-03-17 (actual) (ClinicalTrials.gov record NCT06858878, source copy `cardio:ctgov-nct06858878-2025-12-31`, retrieved 2026-10-26)
- Primary completion: 2027-01-21 (anticipated) (ClinicalTrials.gov record NCT06858878, source copy `cardio:ctgov-nct06858878-2025-12-31`, retrieved 2026-10-26)
- Completion: 2027-04-16 (anticipated) (ClinicalTrials.gov record NCT06858878, source copy `cardio:ctgov-nct06858878-2025-12-31`, retrieved 2026-10-26)
- Countries: United States; Argentina; Bulgaria; Canada; Czechia; Germany; Hungary; Italy; Japan; Poland; Puerto Rico; South Korea; United Kingdom (ClinicalTrials.gov record NCT06858878, source copy `cardio:ctgov-nct06858878-2025-12-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06858878-2025-12-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- Acronym: MARITIME-2
- Condition: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
- Intervention (Drug): Maridebart cafraglutide
- Intervention (Drug): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 1b06844129c4a30057249668782dc5173dcb3569805e6e65dd5acb394c69fa2d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
